Company News 

Hikma’s woes highlight generics challenges

Hikma’s woes highlight generics challenges

In March, Hikma’s (HIK) management was confident the group’s unbranded drugs division could generate $800m of revenue in 2017, a 32 per cent increase on the previous year. That confidence has disappeared. Three warnings from the division in the past eight months mean sales are now expected at $600m, while operating profits look likely to drop from the $35m reported in 2016.  

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now